tag:blogger.com,1999:blog-6520560265126950473.post2222228967810017652..comments2024-02-28T22:44:30.969+05:30Comments on Med-Chemist: Mirati begins dosage in MGCD265 Phase 1b clinical trial for NSCLChttps://www.med-chemist.comhttp://www.blogger.com/profile/00786134978315983333noreply@blogger.comBlogger1125tag:blogger.com,1999:blog-6520560265126950473.post-25557897207757878272015-10-16T12:10:12.398+05:302015-10-16T12:10:12.398+05:30Also, last month, scientists studied and found tha...Also, last month, scientists studied and found that nivolumab is more effective than the traditional drugs like <a href="http://www.bocsci.com/description.asp?cas=114977-28-5&cid=84" rel="nofollow">docetaxel </a> in the treatment for NSCLC, which will promote a better drug development for the disease.Anonymousnoreply@blogger.com